Sandro Porceddu discusses the new Lancet Oncology Series on head and neck cancer.
Michele Cavo discusses the International Myeloma Working Group’s recommendations on the use of 18F-FDG PET/CT for patients with multiple myeloma and other plasma cell dyscrasias.
Lesley Seymour discusses the iRECIST guidelines for assessing tumour responses in immunotherapy trials.
Javier Torres-Roca and Louis Harrison join us to discuss their work on genome modelling and its uses in calculating the appropriate radiation dosage.
Ann Partridge talks about cancer survival in the USA.
Rafael Rossell discusses RET inhibitors and non-small cell lung cancer.
Brigitta Baumert discusses her article on quality of life in patients with high-risk, low-grade glioma.
Brian Rini discusses active surveillance for patients with metastatic renal cell carcinoma.
Shaji Kumar discusses updated consensus criteria from the International Myeloma Working Group for response and minimal residual disease assessment in multiple myeloma.
Catherine Sauvaget and Ryo Konno discuss Japan’s low uptake of screening programmes for breast and cervical cancer.
Anish Thomas discusses use of antibody-drug conjugates for cancer therapy.
Jean-Claude Dupont and François Doz discuss ethical issues in paediatric oncology clinical trials.
Michael Taylor discusses treatment approaches to the rare brain tumour that generally affects children, medulloblastoma.
Sibylle Loibl discusses the findings and clinical implications of the GeparSepto trial.
Dr. Richard Carvajal discusses aspects of treatment and research for rare cancers.
Discussion of two new treatment approaches to indolent lymphoma and mantle-cell lymphoma, haematological diseases with generally poor response to chemotherapy.
Hideho Okada discusses immunotherapy response assessment criteria in neuro-oncology.
Rajendra Badwe discusses treatment options for metastatic breast cancer.
Harry Bear discusses the use of adjuvant and neoadjuvant bevacizumab in the treatment of early breast cancer.
Ane Appelt discusses adopting a watchful waiting approach for patients with rectal cancer who achieved a clinical complete response after chemoradiotherapy.
© 2009-2013 Ebling Library, UW-Madison
750 Highland Ave, Madison, WI, 53705-2221